Genetics and genomics in Peru: Clinical and research perspective

Heinner Guio1,2 | Julio A. Poterico1,3 | Kelly S. Levano4 | Mario Cornejo-Olivas5 | Pilar Mazzetti5,6 | Gioconda Manassero-Morales3 | Manuel F. Ugarte-Gil2,7 | Eduardo Acevedo-Vásquez6,8 | Milagros Dueñas-Roque9,10 | Alejandro Piscoya11,12 | Ricardo Fujita13 | Cesar Sanchez1 | Sandro Casavilca-Zambrano14,15 | Luis Jaramillo-Valverde4 | Yasser Sullcahuaman-Allende15,16 | Juan M. Iglesias-Pedraz2,17 | Hugo Abarca-Barriga18,19,20

1Instituto Nacional de Salud del Perú, Lima, Perú
2Universidad Científica del Sur, Lima, Perú
3Servicio de Genética, Instituto Nacional de Salud del Niño San Borja (INSN-SB), Lima, Perú
4INBIOMEDIC Research and Technological Center, Lima, Perú
5Neurogenetics Research Center, Instituto Nacional de Ciencias Neurológicas, Lima, Perú
6School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Perú
7Rheumatology Department. Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Perú
8Clínica San Felipe, Lima, Perú
9Servicio de Genética, Hospital Nacional Edgardo Rebagliati Martins, Lima, Perú
10Sociedad de Genética Médica del Perú, Lima, Peru
11Universidad San Ignacio de Loyola, Lima, Perú
12Hospital Guillermo Kaclín de la Fuente, Lima, Perú
13Centro de Genética y Biología Molecular, Universidad de San Martín de Porres, Lima, Perú
14Banco de Tejidos Tumorales, Instituto Nacional de Enfermedades Neoplásicas, Banco de Tejidos Tumorales, Lima, Perú
15Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
16Universidad Peruana de Ciencias Aplicadas UPC, Lima, Peru
17Laboratorio de Genética Molecular y Bioquímica, Departamento de Investigación, Desarrollo e Innovación, Universidad Científica del Sur, Lima, Perú
18Servicio de Genética & EIM, Instituto Nacional de Salud del Niño Breña (INSN), Lima, Perú
19Facultad de Estomatología, Universidad Científica del Sur, Lima, Perú
20Facultad de Medicina Humana, Universidad Ricardo Palma, Lima, Perú
1  |  PERUVIAN DEMOGRAPHICS

Peru is a pluricultural and ethnically diverse country located in middle west of South America. It is the fourth largest country (1,285,216 km²) in area in South America, bordered in the north by Ecuador and Colombia, in the south by Chile, south east by Bolivia, by Brazil in the east and by the Pacific Ocean in the west. Peru has one of the most diverse climates, geographical and ecological in the world, from tropical or subtropical dessert to glacial in highland mountains to Amazon jungle. Peru is divided into 24 geopolitical regions with a central government. According to last national census in 2017, Peruvian populations accounts for 31,237,385 inhabitants (Instituto Nacional de Estadistica e Informatica [INEI], 2017). Most of Peru's population lives in the Coastal area, with almost one third of the nation's population living in Lima, the largest city with approximately 11 million people. Rural and urban population has changed over the last 50 years due to migration waves in the 1950s from rural to urban sites mainly located in the coast causing decrease or disappearance of native communities.

The Peruvian health care system in Peru includes five different subsystems: (a) Ministry of Health that provides services to people categorized as poor and extremely poor (around of the population) covered by SIS (Integral Health insurance), (b) Social security subsystem (EsSalud) administered by Labor and Employment Minister that provides services to formal employees and their dependents (26.7% of population), (c) Armed Forces subsystem run by Minister of Defense, (d) Police forces subsystem administered by Ministry of Interior and (e) the Private sector (Alcalde-Rabanal, Lazo-González, & Nigenda, 2011; Ypanaqué-Luyo & Martins, 2015). Within the most prevalent diseases in Peru, upper respiratory infectious (viral or bacterial) diseases have the highest morbidity rates and cancer (gastric, cervical, uterine, breast, prostate, and lung) the highest mortality rates (INEI, 2015). This gives the unique opportunity for diverse genetic studies in the most prevalent infectious and non-infectious diseases afflicting the Peruvian population.

2  |  HEALTHCARE SERVICES OF GENETICS AND GENOMICS

Genetic services in Peru are scarce but growing despite limitations in infrastructure and qualified human resources. The very few public genetic services available in the country offer clinical care and genetic counseling provided by medical geneticists and other specialists with training on genetics. Available molecular diagnosis is mostly based on cytogenetic techniques, PCR-based and Sanger sequencing technologies. There are 21 accredited medical geneticists in national registry of the Peruvian Medical college of Physician (https://cmp.org.pe/conoce-a-tu-medico/) most of them working in public hospitals within the Capital city. Training in human genetics and medical genetics are scarce with only one accredited medical genetics residency program for physicians, one postgraduate program on human genetics and one biology, genetics and bio-technology graduate program for molecular biology specialists. Genetic counseling is currently offered by medical geneticists and other specialists with training in genetics; however, there is no formal accredited Genetic counseling program in Peru. In addition, national and international collaborations have been crucial specially in bioinformatic analysis due to in Peru there is still no university bioinformatics career, the trainings only are part of courses, seminars inside and outside our country.

2.1  |  Newborn screening

There are isolated hospital initiatives for newborn screening in Peru. By 2012, a law state the national interest for having a Universal Newborn screening program, prioritizing screening for congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH), phenylketonuria (PKU), cystic fibrosis, hearing loss and congenital cataract (Galán-Rodas, Duenas, Obando, & Saborio 2013). Up to now, there are independent newborn screening programs in main hospitals of Ministry of Health, Social security (EsSalud) subsystem and private sector. The program from EsSalud started back in 2011 (INEI, 2015), including screening for CH, PKU, CAH, and galactosemia (GAL) available in every single EsSalud healthcare center across the country. The incidence of CH, CAH, PKU, and GAL was 1:3,211, 1:22,207, 1:46,970, and 1:37,576, respectively (Data according to Dr. M. Dueñas). However, Peru has not yet completely implemented National Newborn Screening Program in Public Medical Centers.

2.2  |  Surveillance of birth defects

Since 2012, there is a hospital-based registry for birth defects at the tertiary hospital of the social security subsystem, which is part of contributing to the Latin American Collaborative
Study of Congenital Malformations (ECLAMC) (Cruz-Ticona et al., 2015). The most common birth defects are as follows: congenital heart defects, Down syndrome, cleft lip and/or palate, hydrocephaly and neural tube defects.

2.3 | Pediatric genetics

Clinical genetics started at the Hospital Guillermo Almenara Irigoyen in 1968, with clinical dysmorphology and karyotype diagnostic test without banding (Delgado-Matallana, 2000). Furthermore, clinical dysmorphology flourished at Instituto Nacional de Salud del Niño-Breña (INSN-Breña), with the advantage of being the representative national institute for children’s health. Over the years, all this experience was published as a unique book in dysmorphology linking patient (authorized by parents) images and a succinct clinical and molecular explanation of diseases. This recompilation entitled “Atlas de Dismorfología Pediátrica” (Atlas of Pediatric Dysmorphology) gathered more than 200 syndromes and recognizable clinical cases with Peruvian patients’ pictures (Klein, Gallardo, Chavez, & Abarca, 2012). Furthermore, INSN-Breña is one of the biggest national institutions where patients from Peru and within the MINSA healthcare system receive diagnosis and management. In Table 1, we can observe the frequency of diagnosed genetic disorders in this institution at the Service of Genetic and Inborn Error of Metabolism.

Chromosomal microarray analysis, is the first-tier clinical diagnostic test for patients with intellectual disability, autism spectrum disorders and congenital anomalies (Miller et al., 2010). This technique was implemented and developed at INSN-Breña, revealing etiology in more than 50% of patients with intellectual disability and development delay (Abarca-Barriga, Chávez Pastor, Trubnykova, Vásquez, & Poterico, 2017), with a previous clinical genetic consultation. Furthermore, we found novel variants and demonstrated how loss of copy number variants (CNV) resulted in homozygous deletion in MPLKIP (OMIM #609188) and SUGCT (OMIM #609187) genes, which are causes of Trichothiodystrophy type 4 and glutaric aciduria type 3, respectively (Serna-Infantes et al., 2018). Also, it allowed us to describe a patient with 18p−/18q+ syndrome, adding to the phenotype by describing the persistent microscopic hematuria and aortic pseudocoarctation with descending aorta walls thickening, suggesting Takayasu’s arteritis (Poterico et al., 2017).

Collaboration with European geneticists allowed the report of novel CNVs of the Sonic hedgehog (SHH) limb enhancer ZPA regulatory sequence (ZRS) on chromosome 7q36 and its relationship with specific polysyndactyly syndromes. These microduplications correlated to Laurin–Sandrow syndrome and Haas-type polysyndactyly, according to the ZRS region length (Lohan et al., 2014). Moreover, Peruvian geneticists of INSN described unique

| Genetic disorders | Diagnostic countsa | Percentage |
|------------------|--------------------|------------|
| Down syndrome    | 1,344              | 12.69      |
| Psychomotor retardation | 582 | 5.49      |
| Intellectual disability | 520 | 4.91      |
| Syndromic psychomotor delay | 342 | 3.23      |
| Syndrome Ehlers-Danlos hypermobile | 280 | 2.64      |
| Syndromic intellectual disability | 267 | 2.52      |
| Autism spectrum disorder | 251 | 2.37      |
| Short size       | 202                | 1.91       |
| Syndromic short  | 199                | 1.88       |
| Language delay   | 191                | 1.8        |
| Neurofibromatosis 1 | 159 | 1.5       |
| Syndromic microcephaly | 150 | 1.42      |
| Microtia         | 142                | 1.34       |
| Turner syndrome  | 128                | 1.21       |
| Hemihyperplasia  | 117                | 1.1        |
| Cleft lip-palate | 116                | 1.09       |
| Malformation syndrome | 112 | 1.06      |
| Goldenhar syndrome | 107   | 1.01     |
| Macules café-au-lait | 106 | 1        |
| Skeletal dysplasia | 101   | 0.95     |
| Noonan syndrome  | 96                 | 0.91       |
| Imperfect osteogenesis | 82   | 0.77     |
| Microcephaly     | 75                 | 0.71       |
| Moebius syndrome | 72                 | 0.68       |
| Hypotonia        | 58                 | 0.55       |
| Neural tube defect | 56    | 0.53      |
| Epilepsy         | 56                 | 0.53       |
| Marfanoid syndrome | 56    | 0.53      |
| Disorder of sexual differentiation | 56 | 0.53 |
| Duchenne muscular dystrophy | 52 | 0.49 |
| Palatal cleft    | 49                 | 0.46       |
| Achondroplasia   | 46                 | 0.43       |
| Unbalanced chromosome alteration | 45 | 0.42 |
| Congenital heart disease | 41 | 0.39 |
| Marfan syndrome  | 40                 | 0.38       |
| Congenital multiple arthrogryposis | 39 | 0.37 |
| Overgrowth syndrome | 38   | 0.36      |
| Mucopolysaccharidosis | 36   | 0.34      |
| Poland anomaly   | 35                 | 0.33       |
| Congenital cataract | 34    | 0.32      |
| Macrocephaly     | 34                 | 0.32       |
| Myopathy         | 33                 | 0.31       |

(Continues)
| Genetic disorders                        | Diagnostic counts | Percentage |
|-----------------------------------------|-------------------|------------|
| Williams syndrome                       | 32                | 0.3        |
| Spinal muscular atrophy                 | 31                | 0.29       |
| Sequence of amniotic bands              | 31                | 0.29       |
| Sensorineural hearing loss               | 30                | 0.28       |
| Craniosynostosis                        | 29                | 0.27       |
| Syndromic lip-palatal fissure           | 29                | 0.27       |
| Cardiac malformation                    | 28                | 0.26       |
| Beckwith-Wiedemann syndrome             | 24                | 0.23       |
| Crouzon syndrome                        | 24                | 0.23       |
| Russell-Silver syndrome                 | 23                | 0.22       |
| Syndromic congenital heart disease      | 21                | 0.2        |
| Tuberous sclerosis                      | 21                | 0.2        |
| Sotos syndrome                          | 21                | 0.2        |
| Epileptic encephalopathy                | 20                | 0.19       |
| Cornelia de Lange syndrome              | 20                | 0.19       |
| Syndromic microphthalmia                | 19                | 0.18       |
| McCune-Albright syndrome                | 18                | 0.17       |
| Scoliosis                               | 17                | 0.16       |
| Leukodystrophy                          | 17                | 0.16       |
| Sensory-motor polyneuropathy            | 17                | 0.16       |
| Multiple enchondromatosis               | 16                | 0.15       |
| Holoprosencephaly                       | 16                | 0.15       |
| Hypophosphatemic rickets                | 16                | 0.15       |
| Congenital hypothyroidism               | 15                | 0.14       |
| Congenital lipodystrophy                | 15                | 0.14       |
| Microphthalmia                          | 15                | 0.14       |
| Polydactyly                             | 15                | 0.14       |
| Kabuki syndrome                         | 15                | 0.14       |
| Renal tubular acidosis                  | 14                | 0.13       |
| VACTERL Association                     | 14                | 0.13       |
| Syndromic cleft palate                  | 14                | 0.13       |
| Syndromic cardiac malformation          | 14                | 0.13       |
| Meromelia                               | 14                | 0.13       |
| Micropene                               | 14                | 0.13       |
| Klippel–Feil syndrome                   | 14                | 0.13       |
| Prader–Willi syndrome                   | 14                | 0.13       |
| Waardenburg syndrome                    | 14                | 0.13       |
| Blepharophimosis syndrome—inverted      | 13                | 0.12       |
| epicanthus—palpebral ptosis             |                    |            |
| Cardiofaciocutaneous syndrome           | 13                | 0.12       |
| Marshall syndrome                       | 13                | 0.12       |
| Spondylocostal dysostosis               | 12                | 0.11       |
| Multiple exostosis                      | 12                | 0.11       |
| Congenital hydrocephalus                | 12                | 0.11       |

(Continues)
cases of pterygium-digital keloid dysplasia (Abarca et al., 2014), H syndrome (Abarca Barriga, Trubnykova, Polar Córdoba, Ramos Díaz, & Aviles, 2016), van der Knaap syndrome (Hamilton et al., 2018), and Shawaf-Traboulsi syndrome (Abarca Barriga et al., 2018). Last, international collaboration permitted reports of two common genetic syndromes—that is, Noonan (Kruszka et al., 2018) and Williams-Beuren (Kruszka et al., 2018)—with clinical geneticists of the National Human Genome Research Institute of The National Institutes of Health; and with other geneticists of different sites in the globe, contributing to the worldwide clinical genetics area.

A political decision allowed the Peruvian population to have a novel institution for children’s healthcare. This specialized institute is called Instituto Nacional de Salud del Niño San Borja (INSN-SB) and is a national reference center for complex cases requiring surgical treatment or transplantation. The Genetics Service started in 2015, with a rapid development in clinical and laboratory activities.

The clinical genetics consultations at INSN-SB are carried out by five clinical geneticists, estimating 400 patients attending every month approximately. The most frequent diagnosis is Down syndrome. Evaluation includes an increasing number of patients with diagnosis of cardiac anomalies (e.g., heterotaxy, dilated cardiomyopathy), neurological (e.g., epilepsy, intellectual disability, hearing loss) or behavioral disorders (e.g., autism).

Cytogenetic analyses have been implemented since the establishment of the Genetics Service at INSN-SB, mostly for constitutional analyses. In addition, there are bone marrow studies of children with leukemia, and chromosome fragility test for diagnosis of Fanconi anemia—being the unique center doing this test in Peru. Since 2016, more than 500 blood and almost 200 bone marrow samples have been analyzed. On the other hand, more than 600 samples have been analyzed for detection of genetic alterations in patients with haematological neoplasms. Ongoing research projects with institutional investment involve cardiac anomalies and pharmacogenetics in children with leukemia.

INSN-SB is working on administrative and logistics issues for obtaining equipment and human resources for the implementation of genetic panel test using next-generation sequencing (NGS) in pediatric diseases, such as cardiac anomalies, bone marrow failure syndromes, among others.

### 2.4 Cancer genetics

Clinical genetics and counseling in oncology started in 2006 at the Instituto Nacional de Enfermedades Neoplásicas (National Institute of Neoplastic Diseases—INEN) as a research initiative with public funding. Since that time, genetic consultations have been increasing not only in numbers but also in clinical conditions with internal and external collaborations, as more non-genetics physicians are aware of hereditary conditions. Moreover, the clinical training on genetics has INEN as the unique node for future medical geneticists.

More than 1,500 patients have attended a clinical geneticist consultation; even if reference to the genetic consultation at INEN is <5% annually. For instance, breast cancer represents the more frequent consultation at the Unit of Molecular Biology and Genetics at INEN (Manrique, Sullcahuamán-Allende, & Limache-García, 2013). Collaboration with foreign institutions such as the private Clinic City of Hope, lead the Peruvian clinical geneticists to be part of clinical research on hereditary or familial cancer in Peru.

Abugattas et al. (2015) depicted in an unselected cohort of women with breast cancer that 5% carried BRCA1 (OMIM #113705) or BRCA2 (OMIM #600185) specific genetic
alterations (Latino-variants panel). *BRCA1 185delAG* was the most frequent variant in these patients. However, the technology employed to identify genetic changes involved a catalog of Latino-variants confirmed by Sanger sequencing, not involving other types of pathogenic genetic changes. Long-standing collaboration with City of Hope has been allowing—through a continuous research project—reports of germline variants of patients attending the genetic counseling consultation at INEN. Genetic information helps geneticists to give an appropriate genetic counseling, and an appropriate management.

Current state-of-the art technologies (i.e., NGS) locally implemented at INEN would allow more patients for evaluation and genetic counseling. On the other hand, clinical and laboratory data have allowed Peruvian geneticists to establish international collaborations not only on the area of hereditary of familial breast cancer syndromes (Abugattas et al., 2015), but also on colorectal cancer (CRC) (Rossi et al., 2017) and gastric cancer (GC) predisposition (Slavin et al., 2017), among others.

Moreover, other clinical international collaborations have arisen on CRC and GC. For instance, a large study which included 362 GC patients from Lima, Peru found that *IRF4* (OMIM #601900), *ELMO1* (OMIM #606420), *CLIP4* (OMIM #605736) and *MSC* (OMIM #603628) promoter methylation coupled with a GDMI > 4 are useful molecular tools for GC risk stratification in endoscopic biopsies (Pirini et al., 2017). An interesting study in native Peruvians (Quechua from the Central Andes) did not found an association between candidate SNPs and GC (Zamudio et al., 2016).

Twenty percent of the Latin American countries have developed guidelines for early detection of CRC, and in the last years with the advent of NGS there have been several tests performed to detect hereditary cancer syndromes, especially Lynch syndrome. These studies in Latin America have reported about 18% of patients diagnosed at a young age have pathogenic variants in genes not traditionally associated with CRC (e.g., *ATM* [OMIM #107585], *CHEK2* [OMIM #604373], *BRCA1*, *BRCA2*, *CDKN2A* [OMIM #600160], *PALB2* [OMIM #610355]). *MHJ1* (OMIM #120436) pathogenic variants were more frequent in patients from Peru, Mexico and Chile, whereas *MSH2* (OMIM #609309) pathogenic variants occurred mostly in patients from Colombia and Argentina (Nique Carbajal, Sánchez Renteria, Lettiero, Wernhoff, & Domínguez-Valentin, 2014; Rossi et al., 2017).

### 2.5 Genetics in autoimmune diseases

Several manuscripts have been published on genetic aspects of autoimmune diseases in Peruvian populations; most of them were collaborative efforts. These studies involved patients of tertiary-level hospitals, mainly the Hospitals Guillermo Almenara Irigoyen and Edgardo Rebagliati Martins from the Social Security System, and in the Hospital Cayetano Heredia from the Ministry of Health System. Specific studies relied on autoimmune disorders, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), spondyloarthritis (SpA) and autoimmune hepatitis.

A new variant *HLA-DRB1* (OMIM #142851) (14:02) was reported in the first of this sort of Peruvian studies on RA in 2001 (Castro et al., 2001). A meta-analysis of *HLA-DQA1* (OMIM #146880) polymorphism in Latin American populations included two Peruvian reports on this issue: from the Hospital Guillermo Almenara Irigoyen and the Air Force Army Hospital (Delgado-Vega & Anaya, 2007). Another Latin American collaboration—Genome of RA network consortium (GENAR)—found that the more Amerindian ancestry, the lower odds of fulfilling several RA criteria (Sánchez et al., 2017). On the other hand, Amerindian descendants could have new genetic loci related to RA (Herráez et al., 2013).

In SLE, two Peruvian hospitals (Hospitals Guillermo Almenara Irigoyen and Edgardo Rebagliati Martins) are part of GENLES (Genoma de Lupus Eritematoso Sistémico Network consortium/Genome of SLE network consortium) which is the biggest genetic study in Latin American populations. This cohort has reported that Amerindian ancestry relates to higher genetic load of SLE risk alleles compared to Caucasian (Sanchez et al., 2010) and to a more severe disease (Sánchez et al., 2012). Nevertheless, when two cohorts with a similar ancestry were compared (LUMINA [Lupus in Minorities: Nature vs. Nurture] and GLADEL [Grupo Latino Americano de Estudio de Lupus/Latin American Group for the Study of SLE]), outcome differences could not be explained by Amerindian ancestry (Úgarte-Gil et al., 2015). Furthermore, GENLES, in collaboration with other cohorts from US and Europe, reported several new loci (Langefeld et al., 2017; Úgarte-Gil et al., 2015). As part of a Peruvian SLE Cohort named the Almenara Lupus Cohort, a study of hypomethylation in SLE patients has been started in collaboration with the University of California in San Francisco (UCSF).

Regarding SpA and its main genetic risk (i.e., *HLA-B27* [OMIM #142830]), a Peruvian population from Hospital Cayetano Heredia in 1981 (Alarcon et al., 1981) reported a low frequency of *HLA-B27* antigen. This asseveration affects SpA Peruvian patients (Cuchacovich et al., 2002), explaining in part the low proportion of Peruvian patients suffering with SpA with this genetic marker. Recently, Hospital Guillermo Almenara Irigoyen has found that ankylosing spondylitis patients in Peru not only have a lower prevalence of *HLA-B27* (<30%) but also a high prevalence of *HLA-B39* (almost 50%); the latter variant is expected to have a similar effect than *HLA-B27* in the pathogenesis of the disease (F. Zevallos, MF. Úgarte-Gil, RV. Gamboa-Cardenas, M. Medina-Chinchon, JM. Cucho-Venegas, JL. Alfaro-Lozano,
Z. Rodriguez-Bellido, C. Pastor-Asurza, R. Perich-Campos, unpublished data).

In autoimmune hepatitis, a cohort from the Hospital Guillermo Almenara Irigoyen showed HLA-DR4 (OMIM #600185) and HLA-DR13 markers as the most frequent, similarly to other Latin American countries. Conversely, European-descendant studies reported HLA-DR3 and HLA-DR4 as the most frequent (Cárdenas Ramírez et al., 2018; Padilla et al., 2012).

Furthermore, Peruvian patients—regarding other autoimmune diseases—from the Hospital Edgardo Rebagliati Martins have been also been included in several multinational reports of primary immunodeficiencies (Stray-Pedersen et al., 2017), including STAT1 (OMIM #600555) mutations (Aldave Becerra & Cachay, 2017; Toubiana et al., 2016), hemophagocytic lymphohistiocytosis (Chinn et al., 2018), Wiskott–Aldrich syndrome and X-linked thrombocytopenia (Crestani et al., 2015).

### 2.6 Neurogenetics research

Neurogenetics in Peru offers specialized care for patients and families affected with repeat expansion disorders and other familial neurodegenerative disorders. The only neurogenetics center in Peru, based at the Instituto Nacional de Ciencias Neurologicas (National Institute of Neurological Sciences), was founded in 1995. The Neurogenetics center provides specialized care for patients and families affected with genetic and orphan neurodegenerative disorders (Cornejo-Olivas, Espinoza-Huertas, et al., 2015). By 2000, the CAG repeat analysis of HTT (OMIM #613004), the gene responsible for Huntington disease became the first molecular protocol implemented at this center (Walker et al., 2018). As a national reference center, the outpatient clinic receives patients and families from different regions of Peru, mostly affected with Huntington disease, inherited ataxias, myotonic dystrophy type 1 and other muscular dystrophies, inherited neuropathies, familial Parkinson and Alzheimer disease among others (Cornejo-Olivas, Espinoza-Huertas, et al., 2015; Mazzetti et al., 2015; Walker et al., 2018). Since 2009, neurogenetic care combines multidisciplinary clinical approach, molecular diagnosis, and clinical research.

Large samples of Huntington and inherited ataxia cases provide a better understanding of genetic epidemiology and its impact in public health in these disorders. The first report of Huntington disease, also known as CHOR-HTT, in Peru traces back to 1950, describing a large family from southern Peru (Torres, Mori-Quispe, & Mendoza-Cabanillas, 2006). Further reports during the late 80s and early 90s highlighted a surprisingly high frequency of cases coming from the Cañete Valley—southern Lima, 200 km south to the Capital city (Cuba, 1986; Cuba, Castro, & Benzaquen, 1983; Cuba & Torres, 1989). The large cohort of CHOR-HTT families in Peru have been made significant scientific contributions in the field including genotype-phenotype correlations of late-onset cases (Cornejo-Olivas, Inca-Martínez, et al., 2015) and Huntington-like disorders (Walker et al., 2018), haplotypes analysis suggesting an Amerindian origin of the HTT mutation (Kay et al., 2017) and health-cost analysis highlighting the dramatic burden of CHOR-HTT in the Peruvian population. Since 2012, an outreach clinic, combining both home visits and consultations at primary care center, is offering multidisciplinary care to CHOR-HTT patients and families from the Cañete valley (Vishnevetsky et al., 2018). Inherited ataxic cases followed over the past 10 years is demonstrating a different distribution of dominant ataxias with relative high frequency of spinocerebellar ataxia type 10 or SCA10 (OMIM #603516) in Peruvian population (Bampi et al., 2017; Gheno et al., 2017).

Genetics of Parkinson disease (PD) demonstrates the transcendence of studying populations with different ancestries when looking for pathogenic variants. Since 2007, as part of the Latin American Research Consortium on the Genetics of Parkinson’s Disease (LARGE-PD), the study of genetics of PD in Peruvian population contributed to increased knowledge of PD. The LARGE PD cohort in Peru facilitate the discovery of novel mutations in PARKIN (OMIM #602544) gene (Cornejo-Olivas, Torres, et al., 2015) as well as addressing the frequency and genotype-genotype correlations of pathogenic variants of the LRRK2 (OMIM #609007) gene in Mestizo population from Latin America (Cornejo-Olivas et al., 2017; Mata et al., 2009, 2011).

### 2.7 Genetics and pharmacogenetics in tuberculosis

Tuberculosis (TB) is an infectious disease with high incidence in Peru. It has been shown that TB can occur at different rates among different races, ethnicities, and even families indicating a genetic predisposition to tuberculosis susceptibility. Different studies have been done to identify genetic polymorphisms related to severity and progression of TB disease. Two-locus genotype −2,518 macrophage chemoattractant protein CCL2 (OMIM #158105) GG and −1607 matrix metalloproteinase MMP1 (OMIM #120353) 2G/2G has been found to promote the expression of hyperinflammation in response to Mycobacterium tuberculosis infection, inducing extensive tissue damage and a severe TB disease (Ganchari, Guio, Zhao, & Flores-Villanueva, 2012). Regarding TB progression, some variants located near the enhancer region on chromosome 3q23 also have been found (Luo et al., 2018). Together with the data obtained from the Peruvian Genome Project and these previous studies, it will be possible to define the origins and distribution of these new polymorphisms associated with transmissible and non-transmissible diseases in Peru: integrating Population Genomics knowledge to Public Health.
How our genetic diversity affects our pharmacological therapy is the basis of pharmacogenomics where the genotype of an individual is identified to determine his or her drug metabolic phenotype, predicting the probability of his or her response and minimizing the adverse reactions to achieve a personalized treatment (Rohrer Vitek, Nicholson, Schultz, & Caraballo, 2015; Weinshilboum & Wang, 2004). Even though metabolic genotypes and phenotypes have been widely studied in Caucasian and Asian populations, in many Latin American populations this key information is still missing. The Peruvian Mestizo population’s unique admixture between multiple Native American communities in its region (Harris et al., 2018) results in a distinct population or populations that do not allow for assumptions from existing pharmacogenomics data. Up to date, only two pharmacogenomic studies have included Peruvian Native American samples (Bisso-Machado et al., 2016; Fuselli et al., 2007). Due to Peru’s high rate of TB, researchers are directing their focus toward the role of pharmacogenomics in TB treatment by starting with the identification of the genetic polymorphisms affecting isoniazid and rifampicin (first-line and second-line anti-tuberculous drugs) metabolism and thus affecting the efficacy of the treatment and the induction of adverse effects. Two main research groups (Dr. Heinner Guio’s group at the Peruvian National Institute of Health in collaboration with the Peruvian National Health Strategy for the Prevention and Control of Tuberculosis [ESPNCT[ Guio, Levano, Sánchez, & Tarazona, 2015], and Dr. Ricardo Fujita’s group at the San Martin de Porres University) are identifying the frequency in the Peruvian population of genetic polymorphisms in crucial drug metabolizing enzymes, NAT2 (OMIM #612182) and CYP2E1 (OMIM #124040), that result in phenotypes that could cause either a decrease or an increase in anti-tuberculous drug concentration affecting the efficacy of the treatment. Genotypic and phenotypic assessment will become essential for the evaluation protocol to provide an adequate personalized treatment that increases efficacy and reduces side effects. The concept of “one dose for all” strategy in TB treatment could be an alternative to avoid mono or multidrug resistance in the Mycobacterium tuberculosis.

3 | BASIC AND TRANSLATIONAL RESEARCH ON GENETICS AND GENOMICS

3.1 | An example of the role of Peruvian universities in genetic and genomic research

The Centro de Genetica y Biologia Molecular de la Universidad San Martin de Porres (CGBM-USMP) has conducted studies on rare Mendelian diseases, chronic diseases, pharmacogenetics, immunogenetics and ancestry in Peruvian populations. As expected, in a mestizo population, there are germline variants reported in Europe, Africa, and Asia, whereas other novel variants, probably of Amerindian origin are also frequently found. Some Mendelian diseases studied by this university-research center are ocular, neuromuscular diseases, cancer, among others.

CGBM-USMP studies of glaucoma in different Peruvian families have allowed refinement of the GLC1B (OMIM #606689) locus in the 2q12-q13 chromosomal region, and a candidate gene for the disease is currently being assessed. The study of MYOC (OMIM #601652) (locus GLC1A) has identified both known mutations in European and African-American populations, as well as novel mutations. Interestingly, these variants are correlated with African ancestry (Chincha and Cañete) and the novel are recurrent in Peru, probably indicating an autochthonous founder effect (Guevara-Fujita et al., 2008; Mendoza-Reinoso et al., 2012). Another disease studied at CGBM-USMP is retinitis pigmentosa—which has a genetic heterogeneity, with more than 70 genes—in approximately 100 Peruvian families, having identified the causative mutation in 30 of them. Notably, the Parán community—enclave in a rural area of Lima—with 60 of the 350 inhabitants have retinitis pigmentosa due to germline variants in the RPGR (OMIM #312610) gene located on the chromosome X.

CGBM-USMP team has assessed more than 300 Peruvian patients with muscular dystrophies, most of them with clinical diagnosis of Duchenne disease. The most common type of mutation are exon deletions, although much lower than in other studies (38% vs. 55%–70%). On the other hand, nonsense mutations have a higher prevalence (30%) compared to other reports (10%–15%). It is not known the reason of these results, but it is possible that it is due to founder effects. This group’s research on Peruvian patients with breast cancer has been depicting interesting results. A first analysis of BRCA1 and BRCA2 by Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) in 18 families with suspicion of hereditary breast and ovari cancer syndrome (HBOC), demonstrated four pathogenic variants. Three of these variants have been previously reported (BRCA1: c.302–1G>C and c.815_824dup10; BRCA2: c.5946delIT), but they are absent in the Latino-variants panel mentioned above. On the other hand, a duplication of adenines in exon 15 in BRCA1 (c.4647_4648dupAA, ClinVar SCV000256598.1) and BRCA1 c.4647_4648dupAA were novel pathogenic variants. Interestingly, two exonic and four intronic variants of unknown significance, some of them found recurrently in HBOC Peruvian families and are absent in normal controls and databases (Buleje et al., 2017). Additionally, other universities such as the Universidad Peruana Cayetano Heredia and the Universidad Mayor de San Marcos have made important contributions in genetic and genomic research.
3.2 Fundamentals of biobanking for translational oncology research

Instituto Nacional de Enfermedades Neoplásicas is a public health center, specialized in the prevention, detection, diagnosis, treatment, and rehabilitation of patients affected by neoplastic diseases or malignant tumors. INEN have implemented genetic platforms for diagnosis and research with international collaborations. The administrative area directly linked to development of oncogenomic scientific research in the institute is the Tumor Biobank of INEN (BTT).

BTT collaborates with diverse scientific organizations, hence serving as a platform for translational research in oncology, with implemented laboratories with capacities in: molecular biology, cell culture, image registration, and histotechnology.

In collaboration with the Institute of Research for Development (IRD)—France, BTT researchers described in Peru an unusual clinical presentation of hepatocellular carcinoma (HCC) with noteworthy characteristics compared to those observed in other regions of the world. We described a younger population displaying an abnormal juvenile mean age of 25 years old, and large tumor exceeding 10 cm diameter, and only 11% of HCCs occurred in the setting of cirrhosis (Bertani et al., 2013; Ruiz et al., 2016).

In order to deepen our understanding of the molecular processes ongoing in Peruvian liver tumors, mutation spectrum analysis was carried out on hepatocellular carcinomas from Peruvian patients. Thirty-one exons covering 17 kb in nine genes considered as mutation hotspots in HCC were analyzed: ARID2 (OMIM #609539), AXIN1 (OMIM #603816), BRAF (OMIM #164757), CTNNB1 (OMIM #116806), NFE2L2 (OMIM #600492), H-RAS (OMIM #190020) K-RAS (OMIM #190070), N-RAS (OMIM #164790), and TP53 (OMIM #191170) (Marchio et al., 2014). Such genotypic alterations are unusual elsewhere, as CTNNB1 mutants were found preferentially in non-HBV-associated HCC. The uncommon genetic profile of Peruvian HCC was further confirmed by the conspicuous excess of deletions present in the mutation spectrum, a pattern rarely observed in sporadic cancer and never described so far in HCC (Marchio et al., 2014). The bimodal age-based distribution, the young age of a distinct subgroup, the low rate of associated cirrhosis, and a peculiar mutation spectrum delineate an unusual tumor process ongoing in the Peruvian population.

In the last years, the pediatric department of INEN received an unusually high number of children with primary intracranial sarcomas. Most of them are fusocellular and pleomorphic high-grade sarcomas. BTT with international collaboration allow analysis with NGS of 11 pediatric intracranial sarcomas NOS from Peru; revealing DICER1 (OMIM #606241) pathogenic variants in terms of a distinct methylation signature and the presence of DICER1 alterations (Koelsche et al., 2018).

3.3 Understanding molecular behavior for genetics

Genetic and genomic medicine need the feedback—and vice versa—from basic science for understanding molecular, cellular, and intercellular processes and applications to clinical settings (Shamanna, Croteau, Lee, & Bohr, 2017). Werner protein (WRNp) represents an excellent example of this, with a scientific node in Peru with international collaboration. Werner syndrome (WS) is a rare autosomal recessive and heritable disease with unknown prevalence in Latin American countries, among others. This disease is associated with truncation or non-functional variants of the protein (Orphanet, 2012). Therefore, patients with this condition are prone to premature aging: that is, metabolic disturbances, cardiovascular defects and neoplastic diseases (Orphanet, 2012; Shamanna et al., 2017). Among the latter, a higher risk of a small subset of neoplasms has been reported, with several specific types of cancer reported like thyroid cancer, malignant melanoma, meningioma, soft tissue sarcoma, osteosarcoma, breast cancer, and leukemia (Goto & Ishikawa, 1996; Lauper, Krause, Vaughan, & Monnat, 2013).

It is well known that WRNp is a nuclear protein whose main function is to protect genome integrity (Rossi, Ghosh, & Bohr, 2010), but it has also been detected in the cytoplasm (Kobbe et al., 2002; Shamanna et al., 2016; Slupianek et al., 2011). However, the cytoplasmatic WRNp behavior remains unknown. Tokita et al. recently reported in a genomic evaluation that tumors of patients with WS depicted slight differences in senescence, mitochondrial dysfunction and telomere attrition markers (Tokita et al., 2016). Interesting but uncertain—according to specific population findings—clinical prediction related to WRN dysregulation in some diseases such as cancer, remains to be clarified with WRNp variants different from the truncating or non-functional. For instance, reports have suggested a link between this sort of variants and breast cancer (Wang et al., 2009; Wirtenberger et al., 2006). Indeed, more research of WRNp needs to be carried out to clarify clinical consequences and therapeutic targets development.

Peruvian Professor Iglesias-Pedraz and his foreign colleagues have been trying to elucidate the WRNp function and behavior, demonstrating that immortal cancer cells harboring stable and conditional silencing system for WRNp, reduce de novo protein synthesis prior to any detectable stress response, weakening the cellular proliferation. This alteration is not due to a defect in gene expression nor protein instability (Li et al., 2014), but due apparently to a defect in the proper protein synthesis in WRN-depleted cancer cells. Additional findings have been observed by these scientists; for example, they found WRNp located in the cytoplasm co-sediments with neoplastic diseases or malignant tumors. INEN have implemented genetic platforms for diagnosis and research with international collaborations. The administrative area directly linked to development of oncogenomic scientific research in the institute is the Tumor Biobank of INEN (BTT).
with ribosomal-enriched complex (unpublished data). This finding was noticed years before by Motonaga et al. (2002) in human tissues and recently, Lachapelle et al. (2011) have identified interaction of WRNp with several components of translational machinery. The aforementioned suggests that the collaborating-group of Professor Iglesias-Pedraz could be immersed in an exciting and novel scientific road regarding WRNp.

4 | PERUVIAN GENOME PROJECT

Modern Peruvians carry in their DNA the history of 2.5 million years of evolution and 150,000 years of migration from Africa to Peru or the Americas. Climatic changes and high altitude, different pathogens and interaction with other ethnic groups, have sculpted the genetic variants and genetic expression in the modern Peruvians. The Andes mountains divide Peru in three regions (coast, highlands, and jungle). One third of the Peruvian population lives above 2,500 m.a.s.l. and over 50,000 people reside above 4,000 m.a.s.l (Macsorley, 2001). On the other hand, 60% of the Peruvians that live in the jungle are exposed to different intestinal parasites leaving a particular human being homeostatic condition. Thus, Peruvians represent an unexplored genomic book with unknown genome-environment interaction data.

By 2011, the Peruvian National Institute of Health (Instituto Nacional de Salud del Peru) started the Peruvian Genome Project lead by Dr. Heinner Guio in collaboration with Timothy O’Connor from University of Maryland and Dr. Tarazona from Universidade Federal de Minas Gerais. Despite disparities in research cost (e.g., equipment and supplies) as compared to US (more than 2.5 times) (Sirisena & Dissanayake, 2018), a total of 280 genomes from 17 Native and 13 Mestizo populations have been analyzed (150 genomes were sequenced using whole genome sequencing and 130 using genotype array platform). This study represents the most extensive Native American sequencing project to date. The analysis shows that our Mestizo populations have 60%–70% native genes—in some geographical locations more than 80%. Most of the newly identified SNPs are missense (~60,000) and come from native communities (Harris et al., 2018). Our data demonstrate a high Native ancestry component in the Peruvian population, even as compared to the results obtain in the Mexican genomic project (Belbin, Nieves-Colón, Kenny, Moreno-Estrada, & Gignoux, 2018). Additional studies in genomics of Peruvian populations will help us to understand these new SNPs (Elhaik et al., 2014; Sandoval et al., 2013). No doubt, these new findings from the Peruvian Genome project will enhance genetic research and medical genomics not only for Peruvians, but for Hispanics and Latinos.

5 | CONCLUDING REMARKS

Peru has been working on genetics and genomics despite the lack of national investment. Multidisciplinary healthcare providers have been contributing to the area of genetics in Peru. We have highlighted several examples of achievements in the clinical and research arenas. Moreover, as the number of well-trained professionals increases—in house and abroad—contributing with national and international collaborators, research, and clinical experiences will increase in quality and extension. All the research data shown in this review could not have been done without local and/or international collaborations. In these times where lots of standardized and incoming technologies and data are emerging, collaboration is extremely important for research and its translation to the public health system, helping in the implementation of precision medicine.

ACKNOWLEDGMENTS
INNOVATE Perú: 404-FIDECOM-INNOVATEPERU-RHAC-2016

CONFLICT OF INTEREST
None declared.

ORCID
Heinner Guio https://orcid.org/0000-0003-0078-1188

REFERENCES
Abarca Barriga, H. H., Caballero, N., Trubnykova, M., Castro-Mujica, M. D. C., LaSerna-Infantes, J. E., Vásquez, F. & Hennekam, R. C. (2018). A novel ASPH variant extends the phenotype of Shawal-Traboulsi syndrome. American Journal of Medical Genetics Part A. [Epub ahead of print]. http://doi.wiley.com/10.1002/ajmg.a.40508
Abarca Barriga, H. H., Trubnykova, M., Polár Córdoba, V., Ramos Diaz, K. J., & Aviles, A. N. (2016). Síndrome H: Primer caso pediátrico reportado en América Latina. Revista Chilena De Pediatría, 87(6), 494–499. https://doi.org/10.1016/j.rchipe.2016.03.006
Abarca, H., Mellgren, A. E. C., Trubnykova, M., Haugen, O. H., Høvding, G., Tveit, K. S., … Hennekam, R. C. (2014). Ocular pterygium-digital keloid dysplasia. American Journal of Medical Genetics Part A., 164(11), 2901–2907. https://doi.org/10.1002/ajmg.a.36713
Abarca-Barriga, H. H., Chávez Pastor, M. A., Trubnykova, M., Vásquez, F., & Poterico, J. A. (2017). Análisis de micromatrizes cromosómicas en niños peruanos con retraso del desarrollo psicomotor o discapacidad intelectual. Revista Peruana De Medicina Experimental Y Salud Pública, 34(3), 572. https://doi.org/10.17843/rpmesp.2017.343.2741
Abogattas, J., Llacuachaqui, M., Allende, Y. S., Velásquez, A. A., Velarde, R., Cotrina, J., … Narod, S. A. (2015). Prevalence of
**BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clinical Genetics, 88(4), 371–375.**

Amaron, G. S., Bocanegra, T. S., Gotuzzo, E., Hinostroza, S., Carrillo, C., Vasey, F. B., … Espinoza, L. R. (1981). Reactive arthritis associated with brucellosis: HLA studies. *Journal of Rheumatology, 8*(4), 621–625.

Alcalde-Rabanal, J. E., Lazo-González, O., & Nigenda, G. (2011). The health system of Peru. *Salud Publica De Mexico, 53*(Suppl 2), s243–s254.

Aldave Becerra, J. C., & Cachay, R. E. (2017). A 3-year-old girl with recurrent infections and autoimmunity due to a STAT1 gain-of-function mutation: The expanding clinical presentation of primary immunodeficiencies. *Frontiers in Pediatrics, 5*, 55. https://doi.org/10.3389/fped.2017.00055

Bampi, G. B., Bisso-Machado, R., Hünemeier, T., Gheno, T. C., Furtado, G. V., Veliz-OTani, D., … on behalf of Rede Neurogenetica (2017). Haplotype study in SCA10 families provides further evidence for a common ancestral origin of the mutation. *Neuromolecular Medicine, 19*(4), 501–509. https://doi.org/10.1007/s12017-018-0844-8

Belbin, G. M., Nieves-Colón, M. A., Kenny, E. E., Moreno-Estrada, A., & Gignoux, C. R. (2018). Genetic diversity in populations across Latin America: Implications for population and medical genetic studies. *Current Opinion in Genetics & Development, 53*, 98–104. https://doi.org/10.1016/j.gde.2018.07.006

Bertani, S., Pineau, P., Loli, S., Moura, J., Zimic, M., Deharo, E., … Ruiz, E. (2013). An atypical age-specific pattern of hepatocellular carcinoma in Peru: A threat for Andean populations. *PLoS ONE, 8*(6), e67756. https://doi.org/10.1371/journal.pone.0067756

Bisso-Machado, R., Ramallo, V., Paixão-Côrtes, V. R., Acuña-Alonzo, V., Demarchi, D. A., Sandoval, J. R. S., … Bortolini, M. C. (2016). NAT2 gene diversity and its evolutionary trajectory in the Americas. *The Pharmacogenomics Journal, 16*(6), 559–565. https://doi.org/10.1038/tpj.2015.72

Buleje, J., Guevara-Fujita, M., Acosta, O., Huaman, F. D. P., Danos, P., Murillo, A., … Fujita, R. (2017). Mutational analysis of *BRCA1* and *BRCA2* genes in Peruvian families with hereditary breast and ovarian cancer. *Molecular Genetics & Genomic Medicine, 5*(5), 481–494.

Cárdenas Ramírez, B., Padilla-Machaca, P. M., Mantilla Cruzatti, O., Rivero Román, J., Rondón Leyva, C., Sumire Umeres, J., & Chaman Ortiz, J. C. (2018). Autoimmune hepatitis recurrence and sequencing analysis. *Revista Medica Basadrina, 46*(3), 144–148.

Cafaro, F., Acevedo, E., Ciusani, E., Angulo, J. A., Wollheim, F. A., & Sandberg-Wollheim, M. (2001). Tumour necrosis factor microsatellites and *HLA-DRB1*, *HLA-DQA1*, and *HLA-DQB1* alleles in Peruvian patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases, 60*(8), 791–795. https://doi.org/10.1136/ard.60.8.791

Chinn, I. K., Eckstein, O. S., Peckham-Gregory, E. C., Goldberg, B. R., Forbes, L. R., Nicholas, S. K., … Allen, C. E. (2018). Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. *Blood, 132*(1), 89–100. https://doi.org/10.1182/blood.2017-11-814244

Cornejo-Olivas, M., Espinoza-Huertas, K., Velit-Salazar, M. R., Veliz-OTani, D., Tirado-Hurtado, L, Inca-Martinez, M., … Mazzetti, P. (2015). Neurogenetics in Peru: Clinical, scientific and ethical perspectives. *Journal of Community Genetics, 6*(3), 251–257. https://doi.org/10.1007/s12687-015-0239-z

Cornejo-Olivas, M. R., Inca-Martinez, M. A., Espinoza-Huertas, K., Veliz-OTani, D., Velit-Salazar, M. R., Marca, V., … Mazzetti, P. (2015). Clinical and molecular features of late onset Huntington disease in a Peruvian cohort. *Journal of Huntington’s Disease, 4*(1), 99–105.

Cornejo-Olivas, M. R., Torres, L., Mata, I. F., Mazzetti, P., Rivas, D., Cosentino, C., … Leverenz, J. B. (2015). A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics. *Parkinsonism & Related Disorders, 21*(5), 444–448.

Cornejo-Olivas, M., Torres, L., Velit-Salazar, M. R., Inca-Martinez, M., Mazzetti, P., Cosentino, C., … Mata, I. F. (2017). Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson’s disease (LARGE-PD), a case of ancestry. *NJP Parkinsons Disease, 3*(1), 19.

Crestani, E., Volpi, S., Candotti, F., Giliani, S., Notarangelo, L. D., Chu, J., … Notarangelo, L. D. (2015). Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia. *Journal of Allergy and Clinical Immunology, 136*(5), 1401–1404.e3. https://doi.org/10.1016/j.jaci.2015.08.010

Cruz-Ticona, E., Liñan-Torres, A., Mayorga-Ricalde, G., Ota-Nakasone, A., Gamarra-Diaz, N., & Duenas-Roque, M. (2015). Down Syndrome in newborns at the Edgardo Rebagliati Martins Hospital: A case-control study. *Revista Medicina Basadrina, 9*(1), 15–19.

Cuba, J. M. (1986). A focus of Huntington’s chorea in Peru. *Revue Neurologique, 142*(2), 151–153.

Cuba, J., Castro, C., & Benzaquen, M. (1983). Sobre la epidemiologia de la Corea de Huntington en el Peru. *Revista de Neuro-Psiquiatria, 46*(3/4), 114–120.

Cuba, J. M., & Torres, L. (1989). [8 genealogic trees of families with Huntington’s chorea in Cañete (Peru)]. *Revista Neurologique, 145*(6–7), 482–484.

Cuchacovich, R., Japa, S., Huang, W. Q., Calvo, A., Vega, L., Vargas, R. B., … Espinoza, L. R. (2002). Detection of bacterial DNA in Latin American patients with reactive arthritis by polymerase chain reaction and sequencing analysis. *Journal of Rheumatology, 29*(7), 1426–1429.

Delgado-Matallana, G. (2000). *Historia de la Medicina Peruana en el Siglo. Lima, Peru: Fondo Editorial De La Universidad Nacional Mayor De San Marcos.*

Delgado-Vega, A. M., & Anaya, J.-M. (2007). Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis. *Autoimmunity Reviews, 6*(6), 402–408. https://doi.org/10.1016/j.autrev.2006.11.004

Elhai, E., Tatarinova, T., Chebotarev, D., Piras, I. S., Maria Calò, C., De Montis, A., … Wells, R. S. (2014). Geographic population structure analysis of worldwide human populations infers their biogeographical origins. *Nature Communications, 5*, 3513. https://doi.org/10.1038/ncomms4513

Fuselli, S., Gilman, R. H., Chanock, S. J., Bonatto, S. L., De Stefano, G., Evans, C. A., … Tarazona-Santos, E. (2007). Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. *The Pharmacogenomics Journal, 7*(2), 144–152. https://doi.org/10.1038/sj.tpj.6500407

Galán-Rodas, E., Dueñas, M., Obando, S., & Saborio, M. (2013). Newborn screening in Peru: Where are we going? *Revista Peruana de Medicina Experimental y Salud Publica, 30*(4), 724–725.

Ganachari, M., Guio, H., Zhao, N., & Flores-Villanueva, P. O. (2012). Host gene-encoded severe lung TB: From genes to the
potential pathways. *Genes & Immunity, 13*(8), 605–620. https://doi.org/10.1038/gene.2012.39

Gheno, T. C., Furtado, G. V., Saute, J. A. M., Donis, K. C., Fontanari, A. M. V., Emmel, V. E., … Saraiva-Pereira, M. I. (2017). Spinocebalulibella ataxia type 10: Common haplotype and disease progression rate in Peru and Brazil. *European Journal of Neurology, 24*(7), 892-e36. https://doi.org/10.1111/ene.13281

Goto, M., Ishikawa, Y., & Sugano, H. (1996). Excess of rare cancers in Werner syndrome (adult progeria). *Cancer Epidemiology, Biomarkers & Prevention, 5*, 239–246.

Guevara-Fujita, M. L., Perez-Grossmann, R. A., Estrada-Cuzcano, A., Goto, M., Ishikawa, Y., & Sugano, H. (1996). Excess of rare cancers in Werner syndrome (adult progeria). *Cancer Epidemiology, Biomarkers & Prevention, 5*, 239–246.

Harris, D. N., Song, W., Shetty, A. C., Levano, K. S., Cáceres, O., Hamilton, E. M. C., Tekturk, P., Cialdella, F., van Rappard, D. F., Wolf, N., Guio, H., Levano, K. S., Sánchez, C., & Tarazona, D. (2015). The role of pharmacogenomics in the tuberculosis treatment regime. *Revista Peruana de Medicina Experimental y Salud Poblacional, 32*(4), 794–800.

Hamilton, E. M. C., Tekturk, P., Cialdella, F., van Rappard, D. F., Wolf, N., I. Yalcinkaya, C., … van der Knaap, M. S. (2018). Megalencephalic leukoecephalopathy with subcortical cysts: Characteristics of disease variants. *Neurology, 90*(16), e1395–e1403. https://doi.org/10.1212/WNL.0000000000005334

Harris, D. N., Song, W., Shetty, A. C., Levano, K. S., Cáceres, O., Padilla, C., … Guio, H. (2018). Evolutionary genomic dynamics of Peruvians before, during, and after the Inca Empire. *Proceedings of the National Academy of Sciences, USA, 115*(28), E6526–E6535.

Herráez, D. L., Martínez-Bueno, M., Riba, L., de la Torre, J. G., Sacnún, M., Goñi, M., … Alarcón-Riquelme, M. E. (2013). Rheumatoid arthritis in Latin Americans enriched for Amerindian ancestry is associated with loci in chromosomes 1, 12, and 13, and the HLA class II region: Susceptibility loci for RA in Latin Americans with enriched Amerindian ancestry, *Arthritis & Rheumatism, 65*(6), 1457–1467. https://doi.org/10.1002/art.37923

Instituto Nacional de Estadística e Informática (INEI). (2015). Informatica IINDEE. Perú: Enfermedad de no transmitibles y transmisibles, 2015. INEI.

Instituto Nacional de Estadística e Informática (INEI). (2017). Censos Nacionales 2017: XII de Población, VII De Vivienda y III De Comunidades Indígenas [Internet], Peru. Retrieved from http://www.censos2017.pe/publicaciones

Kay, C., Tirado-Hurtado, I., Cornejo-Olivas, M., Collins, J. A., Wright, G., Inca-Martínez, M., … Hayden, M. R. (2017). The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. *European Journal of Human Genetics, 25*(3), 332–340. https://doi.org/10.1038/ejhg.2016.169

Klein, E., Gallardo, B., Chavez, M., & Abarca, B. H. (2012). *Atlas de Dismorfología Pediátrica. Vol. 1*. Lima, Perú: Instituto Nacional de Salud del Niño.

Koelsche, C., Mynarek, M., Schrimpfl, D., Bertero, L., Serrano, J., Sahm, F., … von Deimling, A. (2018). Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and Dicer1 mutations. *Acta Neuropathologica, 136*(2), 327–337. https://doi.org/10.1007/s00401-018-1871-6

Kruszka, P., Porras, A. R., de Souza, D. H., Moresco, A., Huckstadt, V., Gill, A. D., … Muenke, M. (2018). Williams-Beuren syndrome in diverse populations. *American Journal of Medical Genetics Part A, 176*(5), 1128–1136. https://doi.org/10.1002/ajmg.a.38672

La Serna-Infantes, J., Pastor, M. C., Trubnykova, M., Velásquez, F. C., Sotomayor, F. V., & Barriga, H. A. (2018). Novel contingent gene deletion in peruvian girl with Trichothiodystrophy type 4 and glutaric aciduria type 3. *European Journal of Medical Genetics, 61*(7), 388–392. https://doi.org/10.1016/j.ejmg.2018.02.004

Lachapelle, S., Gagné, J.-P., Garand, C., Desbiens, M., Coulombe, Y., Bohr, V. A., … Lebel, M. (2011). Proteome-wide identification of WRN-interacting proteins in untreated and nuclease-treated samples. *Journal of Proteome Research, 10*(3), 1216–1227. https://doi.org/10.1021/pr100990s

Langefeld, C. D., Ainsworth, H. C., Graham, D. S. C., Kelly, J. A., Comeau, M. E., Marion, M. C., … Vyne, T. J. (2017). Transancestral mapping and genetic load in systemic lupus erythematosus. *Nature Communications, 8*, 16021. https://doi.org/10.1038/ncomms16021

Lauper, J. M., Krause, A., Vaughan, T. L., & Monnat, R. J. (2013). Spectrum and risk of neoplasia in Werner syndrome: A systematic review. *PLoS ONE, 8*(4), e59709. https://doi.org/10.1371/journal.pone.0059709

Li, B., Iglesias-Pedraz, J. M., Chen, L.-Y., Yin, F., Cadenas, E., Reddy, S., … Comai, L. (2014). Downregulation of the Werner syndrome protein induces a metabolic shift that compromises redox homeostasis and limits proliferation of cancer cells. *Aging Cell, 13*(2), 367–378. https://doi.org/10.1111/acel.12181

Lohan, S., Spielmann, M., Doelken, S. C., Flöttmann, R., Muhammad, F., Baig, S. M., … Klopocki, E. (2014). Microduplications encompassing the Sonic hedgehog limb enhancer ZRS are associated with Haas-type polysyndactyly and Laurin-Sandrow syndrome: Microduplications encompassing the Sonic hedgehog limb enhancer. *Clinical Genetics, 86*(4), 318–325. https://doi.org/10.1111/1345-5991.12352

Luo, Y., Suliman, S., Asgari, S., Amariuta, T., Calderon, R., Lecca, L., … Raychaudhuri, S. (2018). Progression of recent *Mycobacterium tuberculosis* exposure to active tuberculosis is a highlyheritable complex trait driven by 3q23 in Peruvians. Retrieved from http://biorxiv.org/lookup/doi/10.1101/401984

Macorley, F. (2001). High altitude medicine and physiology: 3rd ed. M P Ward, J S Milledge, J B West. (Pp 434; pound69.00.) London: Arnold, 2000. ISBN 0-340-75980-1.

Macedo, W., Sequeira, T., Andrade, L., Carvalho, N., … De Souza, D. H. (2018). MRKH2 mutations in patients with Parkinson’s disease in Peru and Uruguay. *Parkinsonism & Related Disorders, 15*(5), 370–373. https://doi.org/10.1016/j.parkreldis.2018.09.002

Mata, I. F., Cosentino, C., Marca, V., Torres, L., Mazzetti, P., Ortega, O., … Zabetian, C. P. (2009). LRRK2 mutations in patients with Parkinson’s disease from Peru and Uruguay. *Parkinsonism & Related Disorders, 15*(5), 370–373. https://doi.org/10.1016/j.parkreldis.2018.09.002

Mata, I. F., Wilhoite, G. J., Yearout, D., Bacon, J. A., Cornejo-Olivas, M., Mazzetti, P., … Ross, O. A. (2011). Lrrk2 p.Q1111H substitution and Parkinson’s disease in Latin America. *Parkinsonism & Related Disorders, 17*(8), 629–631. https://doi.org/10.1016/j.parkreldis.2011.05.003

Mazzetti, P., Inca-Martínez, M., Tirado-Hurtado, I., Milla-Neyra, K., Silva-Paredes, G., Vishnevetsky, A., … Cornejo-Olivas, M. (2015).
Neurogenetics in Peru, example of translational research. Revista Peruana De Medicina Experimental Y Salud Pública, 32(4), 787–793.

Mendoza-Reinoso, V., Patil, T. S., Guevara-Fujita, M. L., Fernández, S., Vargas, E., Castillo-Herrera, W., … Fujita, R. (2012). Novel and known MYOC exon 3 mutations in an admixed Peruvian primary open-angle glaucoma population. Molecular Vision, 18, 2067–2075.

Miller, D. T., Adam, M. P., Aradhya, S., Biesecker, L. G., Brothman, A. R., Carter, N. P., … Ledbetter, D. H. (2010). Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. The American Journal of Human Genetics, 86(5), 749–764. https://doi.org/10.1016/j.ajhg.2010.04.006

Motanaga, K., Itoh, M., Hachiya, Y., Endo, A., Kato, K., Ishikura, H., … Goto, Y. (2002). Age related expression of Werner’s syndrome protein in selected tissues and coexpression of transcription factors. Journal of Clinical Pathology, 55(3), 195–199. https://doi.org/10.1136/jcp.55.3.195

Niñe Carbajal, C., Sánchez Rentería, F., Lettiero, B., Wernhoff, P., & Domínguez-Valentin, M. (2014). Molecular characterization of hereditary colorectal cancer in Peru. Revista De Gastroenterologia Del Peru, 34(4), 299–303.

Orphanet (2012). Werner syndrome [Internet]. Retrieved from https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=902

Padilla, M., Mayorga, R., Carrasco, F., Bedregal, T., Bobadilla, F., Rondón, C., & Chaman, J. (2012). Liver transplantation for autoimmune hepatitis in Peru: Outcomes and recurrence. Annals of Hepatology, 11(2), 222–227.

Pirini, F., Noazin, S., Jahuara-Arias, M. H., Rodriguez-Torres, S., Friess, L., Michailidi, C., … Guerrero-Preston, R. (2017). Early detection of gastric cancer using global, genome-wide and IRF4, ELMO1, CLIP4 and MUC DNA methylation in endoscopic biopsies. Oncotarget, 8, 38501–38516.

Poterico, L., Vásquez, F., Chávez-Pastor, M., Trubnyková, M., Chavesta, F., Chirinos, J., … Barriga, H. (2017). A Peruvian child with 18p-/18q+ syndrome and persistent microscop ic hematuria. Journal of Pediatric Genetics, 06(4), 258–266. https://doi.org/10.1055/s-0037-1604099

Rohrer Vitek, C. R., Nicholson, W. T., Schultz, C., & Caraballo, P. J. (2015). Evaluation of the use of clinical decision support and online resources for pharmacogenomics education. Pharmacogenomics, 16(14), 1595–1603. https://doi.org/10.2217/pgs.15.100

Rossi, B. M., Palmero, E. I., López-Kostner, F., Sarroca, C., Vaccaro, C. A., Spirandelli, F., … Domínguez-Valentin, M. (2017). A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America. BMC Cancer, 17, 623.

Rossi, M. L., Ghosh, A. K., & Bohr, V. A. (2010). Roles of Werner syndrome protein in protection of genome integrity. DNA Repair, 9(3), 331–344. https://doi.org/10.1016/j.dnarep.2009.12.011

Ruíz, E., Rojas Rojas, T., Berrosi, F., Chávez, I., Luque, C., Cano, L., … Bertani, S. (2016). Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru. Heliyon, 2(1), e00052. https://doi.org/10.1016/j.heliyon.2015.e00052

Sánchez, E., García de la Torre, I., Sápnín, M., Goñi, M., Berbottó, G., Páira, S., … Alarcón-Riquelme, M. E. (2017). Effects of Amerindian genetic ancestry on clinical variables and therapy in patients with rheumatoid arthritis. The Journal of Rheumatology, 44(12), 1804–1812. https://doi.org/10.3899/jrheum.160485

Sánchez, E., Rasmussen, A., Riba, L., Acevedo-Vasquez, E., Kelly, J. A., Langefeld, C. D., … Riquelme, M. E. (2012). Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis & Rheumatism, 64(11), 3687–3694. https://doi.org/10.1002/art.34650

Sanchez, E., Webb, R. D., Rasmussen, A., Kelly, J. A., Riba, L., Kaufman, K. M., … Alarcón-Riquelme, M. E. (2010). Genetically determined Amerindian ancestry correlates with increased frequency of risk alleles for systemic lupus erythematosus: Amerindian Ancestry and SLE Risk Alleles. Arthritis & Rheumatism, 62(12), 3722–3729. https://doi.org/10.1002/art.27753

Sandoval, J. R., Salazar-Granara, A., Acosta, O., Castillo-Herrera, W., Fujita, R., Pena, S. D. J., … Santos, F. R. (2013). Tracing the genomic ancestry of Peruvians reveals a major legacy of pre-Columbian ancestors. Journal of Human Genetics, 58(9), 627–634. https://doi.org/10.1038/jhg.2013.73

Shamanna, R. A., Croteau, D. L., Lee, J.-H., & Bohr, V. A. (2017). Recent advances in understanding Werner syndrome. F1000Research, 6, 1779. https://doi.org/10.12688/f1000research.12110.1

Shamanna, R. A., Lu, H., Croteau, D. L., Arora, A., Agarwal, D., Ball, G., … Bohr, V. A. (2016). Camptothecin targets WRN protein: Mechanism and relevance in clinical breast cancer. Oncotarget, 7(12), 13269–13284. https://doi.org/10.18632/oncotarget.7906

Sirisena, N. D., & Dissanyake, V. H. W. (2018). Taking genomics from the bench to the bedside in developing countries. In Genomic medicine in emerging economies (pp. 13–26). Retrieved from https://linkinghub.elsevier.com/retrieve/pii/B97801218115312000023

Slavin, T., Neuhusen, S. L., Rybak, C., Solomon, I., Nehoray, B., Blazer, K., … Weitzel, J. (2017). Genetic gastric cancer susceptibility in the International Clinical Cancer Genomics Community Research Network. Cancer Genetics, 216–217, 111–119. https://doi.org/10.1016/j.can gen.2017.08.001

Slupianek, A., Poplawski, T., Jozwiakowski, S. K., Cramer, K., Pytel, D., Stoczynska, E., … Skorski, T. (2011). BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Research, 71(3), 842–851. https://doi.org/10.1158/0008-5472.CAN-10-1066

Stray-Pedersen, A., Sorte, H. S., Samarakoon, P., Gambin, T., Chinn, I. K., Coban Akdemir, Z. H., … Lupski, J. R. (2017). Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. Journal of Allergy and Clinical Immunology, 139(1), 232–245. https://doi.org/10.1016/j.jaci.2016.05.042

Tokiwa, M., Kennedy, S. R., Risques, R. A., Chun, S. G., Pritchard, C., Oshima, J., … Monnat, R. J. (2016). Werner syndrome through the lens of tissue and tumour genomics. Scientific Reports, 6, 32038. https://doi.org/10.1038/srep32038

Torres, L., Mori-Quispe, N., & Mendoza-Cabanillas, M. (2006). Estudio Clínico Molecular de la Enfermedad de Huntington en Pacientes del Valle de Cañete-Perú. Diagnóstico, 45, 102–108.

Toubiana, J., Okada, S., Hiller, J., Oleastro, M., Lagos Gomez, M., Aldave Becerra, J. C., … Puel, A. (2016). Heterozygous STAT1 gain-of-function mutations underline an unexpectedly broad clinical phenotype. Blood, 127(25), 3154–3164. https://doi.org/10.1182/blood-2015-11-679902

Ugarte-Gil, M. F., Pons-Estel, G. J., Molineros, J., Wojdyla, D., McGwin, G., Nath, S. K., …, Alarcón, G. S. (2015). Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: A commentary. Rheumatology, 55, 436–440.
Vishnevetsky, A., Illanes-Manrique, M., Inca-Martinez, M., Milla-Neyra, K., Sarapura-Castro, E., Mazzetti, P., … Cornejo-Olivas, M. (2018). Neurology outreach clinic for Huntington disease in Peru: Lessons for neurodegenerative diseases. *Neurology, 91*(6), 282–285. https://doi.org/10.1212/WNL.0000000000005940

von Kobbe, C., Karmakar, P., Dawut, L., Opresko, P., Zeng, X., Brosh, R. M., … Bohr, V. A. (2002). Colocalization, physical, and functional interaction between Werner and Bloom syndrome proteins. *Journal of Biological Chemistry, 277*(24), 22035–22044. https://doi.org/10.1074/jbc.M200914200

Walker, R. H., Gatto, E. M., Bustamante, M. L., Bernal-Pacheco, O., Cardoso, F., Castilhos, R. M., … Tumas, V. (2018). Huntington's disease-like disorders in Latin America and the Caribbean. *Parkinsonism & Related Disorders, 53*, 10–20. https://doi.org/10.1016/j.parkreldis.2018.05.021

Wang, Z., Xu, Y., Tang, J., Ma, H., Qin, J., Lu, C., … Shen, H. (2009). A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women. *Breast Cancer Research and Treatment, 118*(1), 169–175. https://doi.org/10.1007/s10549-009-0327-z

Weinshilboum, R., & Wang, L. (2004). Pharmacogenomics: Bench to bedside. *Nature Reviews Drug Discovery, 3*(9), 739–748. https://doi.org/10.1038/nrd1497

Wirtenberger, M., Frank, B., Hemminki, K., Klaes, R., Schmutzler, R. K., Wappenschmidt, B., … Burwinkel, B. (2006). Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. *Carcinogenesis, 27*(8), 1655–1660. https://doi.org/10.1093/carcin/bgi374

Ypanaqué-Luyo, P., & Martins, M. (2015). Utilization of outpatient health services in the Peruvian population. *Revista Peruana de Medicina Experimental y Salud Pública, 32*(3), 464–470.

Zamudio, R., Pereira, L., Rocha, C. D., Berg, D. E., Muniz-Queiroz, T., Sant Anna, H. P., … Kehdy, F. S. G. (2016). Population, epidemiological, and functional genetics of gastric cancer candidate genes in Peruvians with Predominant Amerindian Ancestry. *Digestive Diseases and Sciences, 61*(1), 107–116. https://doi.org/10.1007/s10620-015-3859-6

---

**How to cite this article:** Guio H, Poterico JA, Levano KS, et al. Genetics and genomics in Peru: Clinical and research perspective. *Mol Genet Genomic Med.* 2018;6:873–886. https://doi.org/10.1002/mgg3.533